Page 1

November 5 , 2021 O Oncolytics Biotech® Reports 2021 Third Quarter Development Highlights and Financial Results NCOLYTICS BIOTECH INC Clinical breast cancer data indicate pelareorep - induced changes in blood T cell populations may be a predictive biomarker Advanced collaboration with Roche and AIO by initiating dosing in phase 1/2 GOBLET trial in gastrointestinal cancers Strong financial position with approximately $ 48 million and cash runway into 2023 Management hosting conference call and webcast today at 8:00 a.m. ET SAN DIEGO and CALGARY , AB , Nov. 5 , 2021 / CNW / -- Oncolytics Biotech® Inc. ( NASDAQ : ONCY ) ( TSX : ONC ) today announced its financial results and development highlights for the quarter ended September 30 , 2021. All dollar amounts are expressed in Canadian currency unless otherwise noted . O NCOLYTICS BIOTECH INC . Innately Adaptive ™ " Over the past few months , we achieved key milestones that have advanced pelareorep's development programs and further highlighted the advantages of its broadly applicable mechanism of action , " said Dr. Matt Coffey , President and Chief Executive Officer of Oncolytics Biotech Inc. " These milestones include the reporting of new clinical biomarker data from our AWARE - 1 breast cancer study , which we are pleased to be announcing today . These data further demonstrate pelareorep's immunotherapeutic effects and its ability to synergize with checkpoint inhibition . It also indicates that changes in peripheral blood T cell populations may be predictive of patient response . This exciting finding could improve our chances of success in subsequent studies by allowing for early identification of patients most likely to benefit from pelareorep therapy . We are evaluating this hypothesis as part of our BRACELET - 1 breast cancer trial , which is assessing the safety , efficacy , and pharmacodynamic effects of pelareorep with and without checkpoint inhibition to support the advancement of our lead program to a registrational study . "